Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: phase I clinical study

Gene Therapy volume 20, pages 717–722 (2013)Cite this article

Subjects

Abstract

The purpose of this phase I clinical trial was to evaluate the safety, tolerability and potential efficacy of VM202, naked DNA expressing two isoforms of hepatocyte growth factor, as an adjunct therapy to coronary artery bypass grafting (CABG) in patients with ischemic heart disease (IHD). Nine patients were assigned to receive increasing doses (0.5 to 2.0 mg) of VM202 injected into the right coronary artery (RCA) territory following completion of CABG for the left coronary artery territory. Patients were evaluated for safety and tolerability, and changes in myocardial functions were monitored via echocardiography, cardiac magnetic resonance imaging and myocardial single photon emission computed tomography throughout 6-month follow-up period. No serious complication related to VM202 was observed throughout the 6-month follow-up period. Global myocardial functions (wall motion score index, P=0.0084; stress perfusion, P=0.0002) improved during the follow-up period. In the RCA region, there was an increase in the stress perfusion (baseline vs 3-month, P=0.024; baseline vs 6-month, P=0.024) and also in the wall thickness of the diastolic and systolic phases. Intramyocardial injection of VM202 can be safely used in IHD patients with the tolerable dose of 2.0 mg. In addition, VM202 might appear to have improved regional myocardial perfusion and wall thickness in the injected region.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Mukherjee D, Bhatt DL, Roe MT, Patel V, Ellis SG . Direct myocardial revascularization and angiogenesis—how many patients might be eligible? Am J Cardiol 1999; 84: 598–600; A8.

    Article  CAS  Google Scholar 

  2. Scott R, Blackstone EH, McCarthy PM, Lytle BW, Loop FD, White JA et al. Isolated bypass grafting of the left internal thoracic artery to the left anterior descending coronary artery: late consequences of incomplete revascularization. J Thorac Cardiovasc Surg 2000; 120: 173–184.

    Article  CAS  Google Scholar 

  3. Caputo M, Reeves BC, Rajkaruna C, Awair H, Angelini GD . Incomplete revascularization during OPCAB surgery is associated with reduced mid-term event-free survival. Ann Thorac Surg 2005; 80: 2141–2147.

    Article  Google Scholar 

  4. Naldini L, Vigna E, Narsimhan RP, Gaudino G, Zarnegar R, Michalopoulos GK et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 1991; 6: 501–504.

    CAS  PubMed  Google Scholar 

  5. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251: 802–804.

    Article  CAS  Google Scholar 

  6. Morishita R, Aoki M, Hashiya N, Yamasaki K, Kurinami H, Shimizu S et al. Therapeutic angiogenesis using hepatocyte growth factor (HGF). Curr Gene Ther 2004; 4: 199–206.

    Article  CAS  Google Scholar 

  7. Jayasankar V, Woo YJ, Bish LT, Pirolli TJ, Chatterjee S, Berry MF et al. Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure. Circulation 2003; 108 (Suppl 1): II230–II236.

    Google Scholar 

  8. Funatsu T, Sawa Y, Ohtake S, Takahashi T, Matsumiya G, Matsuura N et al. Therapeutic angiogenesis in the ischemic canine heart induced by myocardial injection of naked complementary DNA plasmid encoding hepatocyte growth factor. J Thorac Cardiovasc Surg 2002; 124: 1099–1105.

    Article  CAS  Google Scholar 

  9. Ahmet I, Sawa Y, Yamaguchi T, Matsuda H . Gene transfer of hepatocyte growth factor improves angiogenesis and function of chronic ischemic myocardium in canine heart. Ann Thorac Surg 2003; 75: 1283–1287.

    Article  Google Scholar 

  10. Yasuda S, Goto Y, Baba T, Satoh T, Sumida H, Miyazaki S et al. Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function. J Am Coll Cardiol 2000; 36: 115–121.

    Article  CAS  Google Scholar 

  11. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S . Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 1997; 95: 2552–2558.

    Article  CAS  Google Scholar 

  12. Jin H, Yang R, Li W, Ogasawara AK, Schwall R, Eberhard DA et al. Early treatment with hepatocyte growth factor improves cardiac function in experimental heart failure induced by myocardial infarction. J Pharmacol Exp Ther 2003; 304: 654–660.

    Article  CAS  Google Scholar 

  13. Cho KR, Choi JS, Hahn W, Kim DS, Park JS, Lee DS et al. Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg 2008; 34: 857–863.

    Article  Google Scholar 

  14. Henry TD, Hirsch AT, Goldman J, Wang YL, Lips DL, McMillan WD et al. Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study. Gene Therapy 2011; 18: 788–794.

    Article  CAS  Google Scholar 

  15. Gu Y, Zhang J, Guo L, Cui S, Li X, Ding D et al. A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia. J Gene Med 2011; 13: 602–610.

    Article  CAS  Google Scholar 

  16. Morishita R, Aoki M, Hashiya N, Makino H, Yamasaki K, Azuma J et al. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 2004; 44: 203–209.

    Article  CAS  Google Scholar 

  17. Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, Koga M et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008; 118: 58–65.

    Article  CAS  Google Scholar 

  18. Carlsson M, Osman NF, Ursell PC, Martin AJ, Saeed M . Quantitative MR measurements of regional and global left ventricular function and strain after intramyocardial transfer of VM202 into infarcted swine myocardium. American journal of physiology. Heart Circ Physiol 2008; 295: H522–H532.

    Article  CAS  Google Scholar 

  19. Saeed M, Saloner D, Do L, Wilson M, Martin A . Cardiovascular magnetic resonance imaging in delivering and evaluating the efficacy of hepatocyte growth factor gene in chronic infarct scar. Cardiovasc Revasc Med 2011; 12: 111–122.

    Article  Google Scholar 

  20. Perin EC, Silva GV, Vela DC, Zheng Y, Baimbridge F, Gahremanpour A et al. Human hepatocyte growth factor (VM202) gene therapy via transendocardial injection in a pig model of chronic myocardial ischemia. J Card Fail 2011; 17: 601–611.

    Article  CAS  Google Scholar 

  21. Nakamura T, Mizuno S . The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. ProcJapan Acad 2010; 86 (6): 588–610.

    CAS  Google Scholar 

  22. Burr AW, Toole K, Chapman C, Hines JE, Burt AD . Anti-hepatocyte growth factor antibody inhibits hepatocyte proliferation during liver regeneration. J Pathol 1998; 185: 298–302.

    Article  CAS  Google Scholar 

  23. Heeschen C, Dimmeler S, Hamm CW, Boersma E, Zeiher AM . Simoons ML. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation 2003; 107: 524–530.

    Article  CAS  Google Scholar 

  24. Pyun WB, Hahn W, Kim DS, Yoo WS, Lee SD, Won JH et al. Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia. Gene Therapy 2010; 17: 1442–1452.

    Article  CAS  Google Scholar 

  25. Hahn W, Pyun WB, Kim DS, Yoo WS, Lee SD, Won JH et al. Enhanced cardioprotective effects by coexpression of two isoforms of hepatocyte growth factor from naked plasmid DNA in a rat ischemic heart disease model. J Gene Med 2011; 13: 549–555.

    Article  CAS  Google Scholar 

  26. Lee Y, Park EJ, Yu SS, Kim DK, Kim S . Improved expression of vascular endothelial growth factor by naked DNA in mouse skeletal muscles: implication for gene therapy of ischemic diseases. Biochem Biophys Res Commun 2000; 272: 230–235.

    Article  CAS  Google Scholar 

  27. Kim KB, Cho KR, Chang WI, Lim C, Ham BM, Kim YL . Bilateral skeletonized internal thoracic artery graftings in off-pump coronary artery bypass: early result of Y versus in situ grafts. Ann Thorac Surg 2002; 74: S1371–S1376.

    Article  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from ViroMed Co., Ltd (06-2006-273-0) and Reyon Pharmaceuticals Co., Ltd, Seoul, Korea.

Author information

Authors and Affiliations

  1. Seoul National University Bundang Hospital, Gyeonggi, Korea

    J S Kim

  2. Seoul National University Hospital, Seoul, Korea

    H Y Hwang, E-A Park, W Lee, J C Paeng, D S Lee, H-K Kim, D-W Sohn & K-B Kim

  3. Cheju Halla General Hospital, Jeju, Korea

    K R Cho

Authors
  1. J S Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Y Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K R Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E-A Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J C Paeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D S Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H-K Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D-W Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K-B Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K-B Kim.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, J., Hwang, H., Cho, K. et al. Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: phase I clinical study. Gene Ther 20, 717–722 (2013). https://doi.org/10.1038/gt.2012.87

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gt.2012.87

Keywords

This article is cited by

Search

Advanced search

Quick links